Release of data from an ongoing randomized clinical trial for sample size adjustment or planning

Statistics in Medicine

Volumn 26, Issue 22, 2007, Pages 4074-4082

  Freidlin, Boris ^a   Korn, Edward L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Administrative analysis; Bayesian analysis; Data monitoring committee; Data release; Interim analysis

Indexed keywords

ACCURACY; ARTICLE; CONFIDENTIALITY; CONTROL GROUP; DATA ANALYSIS; INFORMATION PROCESSING; MATHEMATICAL ANALYSIS; MATHEMATICAL COMPUTING; METHODOLOGY; OUTCOME ASSESSMENT; PLANNING; SAMPLE SIZE; TIME;

BAYES THEOREM; BIOMETRY; HUMANS; INFORMATION DISSEMINATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SAMPLE SIZE; UNITED STATES;

EID: 34548643315     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2842     Document Type: Article

References (45)

1. George SL. A survey of monitoring practices in cancer clinical trials. Statistics in Medicine 1993; 12:435-450.
2. Korn EL, Simon R. Data monitoring committees and problems of lower-than-expected accrual or events rates. Controlled Clinical Trials 1996; 17:526-535.
3. Friedman L, Furberg CD, DeMets DL. Fundamentals of Clinical Trials (3rd edn). Springer: New York, 1999.
4. PMA Biostatistics and Medical Ad Hoc Committee on Interim Analysis. Interim analysis in the pharmaceutical industry. Controlled Clinical Trials 1993; 14:160-173.
5. Church TR, Ederer F, Mandel JS, Watt GD, Geisser MS. Estimating the duration of ongoing prevention trials. American Journal of Epidemiology 1993; 137:797-810.
6. Grant AM, Altman DG, Babiker AB, Campbell MK, Clemens FJ, Darbyshire JH, Elbourne DR, McLeer SK, Parmar MK, Pocock SJ, Spiegelhalter DJ, Sydes MR, Walker AE, Wallace SA, DAMOCLES Study Group. Issues in data monitoring and interim analysis of trials. Health Technology Assessment 2005; 9:1-238.
7. Fleming TR, DeMets DL. Monitoring of clinical trials: issues and recommendations. Controlled Clinical Trials 1993; 14:183-197.
8. Friedman L. The NHLBI model: a 25 year history. Statistics in Medicine 1993; 12:425-431.
9. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. Risk factor changes and mortality results. Journal of the American Medical Association 1982; 248:1465-1477.
10. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. The New England Journal of Medicine 1989; 321:129-135.
11. Ederer F, Church TR, Mandel JS. Sample sizes for prevention trials have been too small. American Journal of Epidemiology 1993; 137:787-796.
12. Williams GW, Davis RL, Getson AJ, Gould AL, Hwang IK, Matthews H, Shih WJ, Snapinn SM, Walton-Bowen KL. Monitoring of clinical trials and interim analyses from a drug sponsor's point of view. Statistics in Medicine 1993; 12:481-492.
13. Wittes J, Brittain E. The role of internal pilot studies in increasing the efficiency of clinical trials. Statistics in Medicine 1990; 9:65-71.
14. Betensky RA, Tierney C. An examination of methods for sample size recalculation during an experiment. Statistics in Medicine 1997; 16:2587-2598.
15. Zucker DM, Wittes JT, Schabenberger O, Brittain E. Internal pilot studies II: comparison of various procedures. Statistics in Medicine 1999; 18:3493-3509.
16. Green SJ, Fleming TR, O'Fallon JR. Policies for study monitoring and interim reporting of results. Journal of Clinical Oncology 1987; 5:1477-1484.
17. Pocock SJ. Statistical and ethical issues in monitoring clinical trials. Statistics in Medicine 1993; 12:1459-1469.
18. Ellenberg SS, Fleming TR, DeMets DL. Data Monitoring Committees in Clinical Trials. Wiley: Chichester, 2002.
19. Ellenberg S. The use of data monitoring committees in clinical trials. Drug Information Journal 1996; 30:553-557.
20. Herson J, Wittes J. The use of interim analysis for sample size adjustment. Drug Information Journal 1993; 27:753-760.
21. O'Neill RT. Some FDA perspectives on data monitoring in clinical trials in drug development. Statistics in Medicine 1993; 12:601-608.
22. European Medicines Agency. Reflection paper on methodological issues in confirmatory clinical trials with flexible design and analysis plan. Draft http://www.emea.eu.int/pdfs/human/ewp/245902en.pdf (April 2006).
23. Food and Drug Administration. Establishment and operation of clinical trial data monitoring committees. http://www.fda.gov/cber/gdlns/ clintrialdmc.pdf (April 2006).
24. Pocock S, Furberg CD. Procedures of data and safety monitoring committees. American Heart Journal 2001; 141:289-294.
25. DeMets DL, Furberg CD, Friedman LM. Data Monitoring in Clinical Trials A Case Study Approach. Springer: New York, 2005.
26. Gould AL. Interim analyses for monitoring clinical trials that do not materially affect the type I error rate. Statistics in Medicine 1992; 11:55-66.
27. Shih WJ, Zhao PL. Design for sample size re-estimation with interim data for double-blind clinical trials with binary outcomes. Statistics in Medicine 1997; 16:1913-1923.
28. Cook TD. Methods for mid-course corrections in clinical trials with survival outcomes. Statistics in Medicine 2003; 22:3431-3447.
29. Gould AL. Sample size re-estimation: recent developments and practical considerations. Statistics in Medicine 2001; 20:2625-2643.
30. Friede T, Kieser M. A sample size recalculation in internal pilot study design: a review. Biometrical Journal 2006; 48:537-555.
31. George SL, Desu MM. Planning the size and duration of a clinical trial studying the time to some clinical event. Journal of Chronic Diseases 1974; 27:15-24.
32. Geisser S. Predictive Inference: An Introduction. Chapman & Hall: New York, 1993.
33. Lee PM. Bayesian Statistics: An Introduction (2nd edn). Arnold: London, 1997.
34. Tan SB, Smith AF. Exploratory thoughts on clinical trials with utilities. Statistics in Medicine 1998; 17:2771-2791.
35. Box GEP, Tiao GC. Bayesian Inference and Statistical Analysis. Wiley: New York, 1992.
36. George SL, Li C, Berry DA, Green MR. Stopping a clinical trial early: frequentist and Bayesian approaches applied to a CALGB trial in non-small-cell lung cancer. Statistics in Medicine 1994; 13:1313-1327.
37. Qian J, Stangl DK, George SL. A Weibul model for survival data: using prediction to decide when to stop a clinical trial. In Bayesian Biostatistics, Berry DA, Stangl DK (eds). Marcel Dekker: New York, 1996.
38. Chu H, Halloran ME. Bayesian estimation of vaccine efficacy. Clinical Trials 2004; 1:306-314.
39. Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, Miller M, Barchuk WT, Fischkoff S, Kaul M, Teoh L, Van Meter L, Daum L, Lemeshow S, Hicklin G, Doig C, Monoclonal Anti-TNF: a Randomized Controlled Sepsis Study Investigators. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Critical Care Medicine 2004; 32:2173-2182.
40. Berry DA, Ho CH. One-sided sequential stopping boundaries for clinical trials: a decision-theoretic approach. Biometrics 1988; 44:219-227.
41. Spiegelhalter DJ, Freedman LS, Parmar MKB. Bayesian approaches to randomized trials. Journal of the Royal Statistical Society, Series A 1994; 157:357-416.
42. Fayers PM, Ashby D, Parmar MK. Tutorial in biostatistics Bayesian data monitoring in clinical trials. Statistics in Medicine 1997; 16:1413-1430.
43. Dignam JJ, Bryant J, Wieand HS, Fisher B, Wolmark N. Early stopping of a clinical trial when there is evidence of no treatment benefit: protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project. Controlled Clinical Trials 1998; 19:575-588.
44. Korn EL, Freidlin B. A posterior tale. Biometrical Journal 2007, in press.
45. Berry DA, Wolff MC, Sack D. Decision making during a phase III randomized controlled trial. Controlled Clinical Trials 1994; 15:360-378.